Recombinant IL2RA (Basiliximab Biosimilar) anticorps

N° du produit ABIN5668050

Détail du produit anti-IL2RA (Basiliximab Biosimilar) anticorps

Antigène: IL2RA (Basiliximab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain, Cynomolgus, Macaque rhésus

Hôte: Human

Clonalité: Chimeric

Conjugué: Cet anticorp IL2RA (Basiliximab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), Blocking Reagent (BR), Immunofluorescence (IF), Immunohistochemistry (IHC), Western Blotting (WB)

Specificité: Basiliximab recognises the human IL-2R and binds to the epitope (116)ERIYHFV(122) within the extracellular domain of the CD25 subunit - binding is abolished when 2 or more residues within the epitope are mutated. This epitope overlaps with the interaction site of CD25 and IL-2. CD25 is found in the high-affinity IL-2R (αβγc) - T cells only express CD25 upon activation. IL-2 binding to IL-2R on T cells modulates proliferation and differentiation.

Réactivité croisée: Cynomolgus, Macaque rhésus

Attributs du produit:

OriginalSpeciesName: Human

OriginalFormat: IgG1

Purification: Purified antibody.

Pureté: > 98 % as determined by SDS-PAGE

niveau d'endotoxine: Endotoxin is < 1.0 EU/mg as determined by the LAL method

Immunogène: Basiliximab was prepared by immunizing BALB/c mice with CTC 16 cells.

Isotype: IgG1 kappa

Information d'application

Indications d'application: Basiliximab is derived from the murine anti-Tac antibody. For the clinically used format, the variable regions from this antibody were grafted onto the sequence of the human IgG1? constant regions. Basiliximab binding to CD25 competitively blocks the interaction of IL-2R with its ligand IL-2 on the surface of T cells. Blocking this interaction prevents T cell replication and T cell-mediated B cell activation. Basiliximab binding suppresses the immune system inhibits the pathway activating the cellular immune response to allograft rejection. IL-2 signalling suppression can additionally prevent acute graft-versus-host disease, autoimmune disorders and malignancies such as T cell leukemias (Binder et al, 2007). Basiliximab has also been used in FC, IF, IHC and WB studies, which enables the detection of CD25.

Commentaires:

NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques.

Restrictions: For Research Use only

Stockage

Buffer: PBS with 0.02 % Proclin 300.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Détails sur IL2RA (Basiliximab Biosimilar)

Antigène: IL2RA (Basiliximab Biosimilar)

Abstract: IL2RA (Basiliximab Biosimilar) Produits

Synonymes: anticorps CD25, anticorps IDDM10, anticorps IL2R, anticorps TCGFR, anticorps IL2RAC, anticorps Il2r, anticorps Ly-43, anticorps interleukin 2 receptor subunit alpha, anticorps interleukin 2 receptor, alpha chain, anticorps IL2RA, anticorps Il2ra

Sujet: Interleukin-2 receptor subunit alpha, IL-2 receptor subunit alpha, IL-2R subunit alpha, IL-2-RA, IL2-RA, TAC antigen, p55, CD25.

UniProt: P01589